Go Pro
NASDAQ:CAMP

CAMP4 Therapeutics (CAMP) Stock Price, News & Analysis

CAMP4 Therapeutics logo
$4.24 -0.26 (-5.78%)
Closing price 08/7/2026 04:00 PM Eastern
Extended Trading
$4.24 +0.00 (+0.12%)
As of 08/7/2026 05:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About CAMP4 Therapeutics Stock (NASDAQ:CAMP)

Advanced

Key Stats

Today's Range
$4.15
$4.60
50-Day Range
$3.01
$4.50
52-Week Range
$1.32
$7.75
Volume
95,152 shs
Average Volume
207,670 shs
Market Capitalization
$220.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.36
Consensus Rating
Moderate Buy

Company Overview

CalAmp Corp. is a global technology solutions provider founded in 1981 that offers businesses and consumers a wide range of software and hardware products and services worldwide. The company is headquartered in Irvine, California, with additional offices in Europe and Asia. CalAmp has a history of innovation and has received numerous industry awards for its products and services. Key highlights of the company's achievements include acquiring LoJack Corporation, a leader in vehicle theft recovery and advanced fleet management solutions and the launch of CalAmp iOn, a cloud-based platform for managing IoT (Internet of Things) devices.

Calamp's revenue has declined an average of -7.95% yearly, 12.07 percentage points lower than the US Communication Equipment industry's average revenue growth rate of 4.13%. CalAmp shed its satellite communications business in 2020, which resulted in a one-time gain of $85 million. CalAmp's stock performance has declined since 2018 from a peak of around $24.00 a share to a low of approximately $3.00. Despite this, the company could gain momentum as it recently announced a restructuring plan to transition to a cloud-based IOT platform.  

CalAmp operates in the technology solutions industry, rapidly evolving due to the increasing use of digital technologies across various sectors. The company's main competitors include industry giants like Cisco Systems, Inc. and Honeywell International Inc., as well as smaller companies like Fleet Complete and Orbcomm Inc. The industry is subject to various regulatory and political issues, including data privacy and security concerns, which can significantly impact the industry's growth and profitability.

CalAmp's management team is led by CEO Jeff Gardner, who has over 25 years of experience in the technology industry. Other key team members include the recent addition of CFO Kurt Binder, who has a history of succeeding in challenging business environments and CTO Anand Rau, who has 25 years of strategic management experience in delivering enterprise-class, mission-critical applications. 

CalAmp has identified several potential growth opportunities, including expanding its IoT platform, CalAmp iOn, into new markets, such as healthcare and agriculture. The company is also exploring new product launches, such as its recently launched connected car solution, which allows vehicle owners to monitor and manage their vehicles remotely. Additionally, CalAmp is actively pursuing acquisitions to expand its product and service offerings and increase its market share.

The technology industry is highly competitive, and CalAmp faces significant competition from larger, more established companies. The industry is also subject to rapid technological change, which can quickly make existing products and services obsolete. CalAmp must continue to innovate and stay ahead of the curve to maintain its market position. Additionally, the industry is subject to regulatory and political risks, including data privacy and security concerns, which can impact the industry's growth and profitability.

CAMP4 Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
81st Percentile Overall Score

CAMP MarketRank™: 

CAMP4 Therapeutics scored higher than 81% of companies evaluated by MarketBeat, and ranked 116th out of 902 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    CAMP4 Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on no strong buy ratings, 7 buy ratings, no hold ratings, and 2 sell ratings.

  • Upside Potential

    CAMP4 Therapeutics has a consensus price target of $8.36, representing about 97.1% upside from its current price of $4.24.

  • Amount of Analyst Coverage

    CAMP4 Therapeutics has only been the subject of 4 research reports in the past 90 days.

  • Read more about CAMP4 Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for CAMP4 Therapeutics are expected to grow in the coming year, from ($0.84) to ($0.74) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of CAMP4 Therapeutics is -1.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of CAMP4 Therapeutics is -1.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    CAMP4 Therapeutics has a P/B Ratio of 4.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    3.55% of the float of CAMP4 Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    CAMP4 Therapeutics has a short interest ratio ("days to cover") of 9.1.
  • Change versus previous month

    Short interest in CAMP4 Therapeutics has recently increased by 9.98%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    CAMP4 Therapeutics does not currently pay a dividend.

  • Dividend Growth

    CAMP4 Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    CAMP4 Therapeutics has a news sentiment score of 1.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 14 news articles for CAMP4 Therapeutics this week, compared to 3 articles on an average week.
  • Search Interest

    Only 2 people have searched for CAMP on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added CAMP4 Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Cluster Insider Buying

    4 insiders have purchased shares of CAMP4 Therapeutics in the last three months. Multiple insiders buying is a strong bullish signal.

  • Net Insider Buying

    Over the last three months, insiders have purchased a net $59,451.00 in company stock, which represents 0.0270% of the company's market cap.

  • Insider Buying vs. Insider Selling

    In the past three months, CAMP4 Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $59,451.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    21.69% of the stock of CAMP4 Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    CAMP4 Therapeutics has minimal institutional ownership at this time.

  • Read more about CAMP4 Therapeutics' insider trading history.
Receive CAMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CAMP4 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CAMP Stock News Headlines

CAMP4 CEO on landmark SYNGAP1 trial
SpaceX pays a 10X launch penalty
SpaceX burns roughly $200,000 in fuel per Falcon 9 launch - about $20 million across 100 missions. One under $5 company's High Altitude Head Start technology could bring that down to $20,000 per launch, or $2 million across 100 missions - a 10X cost advantage. It is already flying with paying customers, but shares may not stay this cheap once Wall Street notices.tc pixel
See More Headlines

CAMP Stock Analysis - Frequently Asked Questions

CAMP4 Therapeutics' stock was trading at $6.0850 on January 1st, 2026. Since then, CAMP stock has decreased by 30.3% and is now trading at $4.24.

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) announced its quarterly earnings data on Thursday, November, 6th. The Wireless communications provider reported ($0.55) EPS for the quarter, missing analysts' consensus estimates of ($0.47) by $0.08. The Wireless communications provider earned $0.80 million during the quarter. CAMP4 Therapeutics had a negative trailing twelve-month return on equity of 194.74% and a negative net margin of 2,193.72%.

CAMP4 Therapeutics's stock reverse split before market open on Friday, February 2nd 2024.The 1-23 reverse split was announced on Friday, February 2nd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

CAMP4 Therapeutics subsidiaries include these companies: LoJack, Gulfstream Telematics, SmartLink Radio Networks, CalAmp Wireless Networks Inc., Skybility, Boisen S.A., CalAmp Importation and Leasing of Tracking Equipment Ltd., and others.

CAMP4 Therapeutics (CAMP) raised $102 million in an IPO on Friday, October 11th 2024. The company issued 6,820,000 shares at a price of $14.00-$16.00 per share.

Top institutional investors of CAMP4 Therapeutics include BlackRock Inc. (3.17%), Bank of New York Mellon Corp (0.16%) and Deutsche Bank AG (0.06%). Insiders that own company stock include 5Am Partners Vi, Llc, Polaris Management Co Vii, L, Amir Nashat, Josh Mandel-Brehm, Richard A Young, Kelly Gold, Yuri Maricich and Jason Cohenour.
View institutional ownership trends
.

Shares of CAMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that CAMP4 Therapeutics investors own include Zimmer Biomet (ZBH), Union Pacific (UNP), Charter Communications (CHTR), NVIDIA (NVDA), PayPal (PYPL), MercadoLibre (MELI) and Meta Platforms (META).

Company Calendar

Last Earnings
11/06/2025
Today
8/08/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CAMP
CIK
730255
Employees
644
Year Founded
1981

Price Target and Rating

High Price Target
$12.00
Low Price Target
$6.50
Potential Upside/Downside
+97.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.56
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.36)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$80.40 million
Net Margins
-2,193.72%
Pretax Margin
-2,193.72%
Return on Equity
-194.74%
Return on Assets
-95.64%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.15
Quick Ratio
6.15

Sales & Book Value

Annual Sales
$3.50 million
Price / Sales
62.91
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.02 per share
Price / Book
4.16

Miscellaneous

Outstanding Shares
51,930,000
Free Float
40,663,000
Market Cap
$220.18 million
Optionable
No Data
Beta
0.22

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

This page (NASDAQ:CAMP) was last updated on 8/8/2026 by MarketBeat.com Staff.
From Our Partners